BFM
FTH

Boothbay Fund Management’s Faeth Therapeutics FTH Stock Holding History

Boothbay Fund Management’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.34M Buy
133,643
+107,519
+412% +$2.49M 0.04% 487
2026
Q1 		$823K Buy
+26,124
New +$522K 0.01% 1045
2025
Q2 		– Sell
-5,433
Closed -$42.8K – 1746
2025
Q1 		$42.8K Sell
5,433
-3,207
-37% -$30.5K ﹤0.01% 1293
2024
Q4 		$84.7K Sell
8,640
-2
-0% -$20 ﹤0.01% 1308
2024
Q3 		$103K Hold
8,642
– – ﹤0.01% 1456
2024
Q2 		$107K Buy
+8,642
New +$180K ﹤0.01% 1343

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Boothbay Fund Management's FTH Position: Q2 2026 in Review

Boothbay Fund Management increased its Faeth Therapeutics (FTH) stake by 412% in Q2 2026, buying an estimated $2.49M and bringing the position to 133,643 shares worth $3.34M. The position accounts for 0.04% of the portfolio, ranked #487.

Boothbay Fund Management first reported a position in FTH in Q2 2024 and has held it in 6 quarters since. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Boothbay Fund Management held 133,643 shares of Faeth Therapeutics worth $3.34M as of Q2 2026.
  • Boothbay Fund Management bought 107,519 Faeth Therapeutics shares in Q2 2026, an estimated $2.49M.
  • Faeth Therapeutics made up 0.04% of Boothbay Fund Management's portfolio in Q2 2026, its #487 holding.
  • Boothbay Fund Management first reported a position in Faeth Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.